‘Stuck’ at sea: Coronavirus challenges cruise industryCornell University
As hospitalized COVID-19 patients undergo experimental therapy, research published in the Journal of Biological Chemistry explains how the drug, remdesivir, stops replication in coronaviruses.
Led by Tony Hu, the Weatherhead Presidential Chair in Biotechnology Innovation at Tulane University School of Medicine, researchers are now developing a rapid, reliable and highly specific test to allow rapid diagnosis of all forms of Tuberculosis (TB).
Findings from CT scans provide new insight that could lead to quicker diagnosis
The research team found that CBG had antibacterial activity against drug-resistant MRSA. It prevented the ability of that bacteria to form biofilms, which are communities of microorganisms that attach to each other and to surfaces; and it destroyed preformed biofilms and cells resistant to antibiotics. CBG achieved this by targeting the cell membrane of the bacteria. These findings in the laboratory were supported when mice with an MRSA infection were given CBG.
A new study has uncovered key details for how the Salmonella bacteria that causes typhoid fever identifies a host’s immune cells and delivers toxins that disrupt the immune system and allow the pathogen to spread.
As of Feb. 25, 2020, the World Health Organization reported 79,339 confirmed cases of novel coronavirus, also known as COVID-19. Thirty-four countries have reported cases, including 2,619 deaths.The WHO has not declared COVID-19 as a pandemic — a situation defined somewhat vaguely by the WHO as “the worldwide spread of a new disease.
Interacting contagious diseases like influenza and pneumonia—and perhaps coronavirus too—follow the same complex spreading patterns as social trends, like the adoption of new slang or technologies. This new finding, published in Nature Physics, could lead to better tracking and intervention when multiple diseases spread through a population at the same time.